Clinical Trials Directory

Trials / Completed

CompletedNCT03117491

Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Isfahan University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Introduction: to evaluate the efficacy of inferior alveolar nerve block (IANB), Gow-Gates nerve block (GGNB), and their combination in patients with irreversible pulpitis. Methods: One hundred fifty subjects with irreversible pulpitis of a mandibular molar were selected. subjects randomly received two IANB injections or two GGNB injections or their combination of 1.8 mL 2% lidocaine with 1:100,000 epinephrine. Success was specified as no or mild pain on the basis of Heft-Parker visual analogue scale recordings up on the access cavity preparation or initial instrumentation. Data were analyzed by Kruskal-Wallis, and ANOVA tests.

Detailed description

Introduction: to evaluate the efficacy of inferior alveolar nerve block (IANB), Gow-Gates nerve block (GGNB), and their combination in patients with irreversible pulpitis. Methods: One hundred fifty subjects with irreversible pulpitis of a mandibular molar were selected. subjects randomly received two IANB injections or two GGNB injections or their combination of 1.8 mL 2% lidocaine with 1:100,000 epinephrine. Success was specified as no or mild pain on the basis of Heft-Parker visual analogue scale recordings up on the access cavity preparation or initial instrumentation. Data were analyzed by Kruskal-Wallis, and ANOVA tests.

Conditions

Interventions

TypeNameDescription
PROCEDUREGGNB injectionsThe patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
PROCEDUREIANB injectionsThe patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
PROCEDUREGGNB + IANB injectionsThe patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine

Timeline

Start date
2015-12-01
Primary completion
2016-11-01
Completion
2016-12-01
First posted
2017-04-18
Last updated
2017-05-09

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT03117491. Inclusion in this directory is not an endorsement.